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1. Introduction
A stem-cell niche can be defined as a spatial structure in which stem cells are housed and
maintained by allowing self-renewal in the absence of differentiation. The concept of the stem-
cell niche was initially proposed in invertebrates where they were first characterized; the
control of germ line stem cell maintenance and differentiation was observed in ovarian and
testicular D. melanogaster niches (Wilson & Trumpp, 2006).
Hematological stem cells (HSCs) can be initially identified in the developing embryo in aorta-
gonada-mesonephro regions, form where they migrate into the fetal liver and subsequently
move into the bone marrow (BM) after birth. During development, HSCs undergo active self-
renewal to expand the pool size, but then become largely quiescent and stay in a steady state
in adult BM, where their maintenance is tightly regulated (Oh & Kwon, 2010).
The link between bone-marrow formation (hematopoiesis) and bone development (osteogen‐
esis) was first recognized in the 1970s. It was noted that whilst HSCs in the bone marrow drive
hematopoiesis during the whole life of organisms, when they are removed from the bone
marrow, they lose the ability to self-renewal, indicating similar dependence of HSCs on
extrinsic signals (Lilly et al., 2011). The term 'niche' used for the specific HSC bone-marrow
microenvironment was first coined by Schofield (1978), who observed that HSC growth was
not supported in the spleen in the same manner as in the bone marrow; he also proposed that
HSCs are in intimate contact with bone, and that cell–cell contact was responsible for the
apparently unlimited proliferative capacity and inhibition of maturation of HSCs.
This concept has since been further developed, and it is now widely accepted that specific
anatomical regions within the bone marrow comprise specialized niches for HSC development
© 2013 Bydlowski et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
and normal blood cell production (Noll et al., 2012). The niche is composed of a vast milieu of
cellular and humoral factors.
The advancement of our understanding of the interactions between bone, the microenviron‐
ment and hematopoiesis is rapidly accelerating. Research continues on the identification and
characterization of individual cell populations constituting the hematopoietic stem cell (HSC)
niche. Whether there are one or multiple HSC niches and how cells within the HSC niche
interact with each other are also subjects of interest (Shen et al., 2012).
Recently it has been suggested that two main microenvironments form the bone marrow
niches: 1. the endosteal niche, where osteoblasts derived from mesenchymal precursors are
localized in the endosteal regions, and 2. The vascular niche, which might be involved in HSC
maintenance within the bone marrow (Chotinantakul et al., 2012).
2. The endosteal niche
The first direct evidence for cells having stem cell-supporting activity in bone formation was
provided by studies in which both mouse and human osteoblast cell lines were shown to
secrete a large number of cytokines that promote the proliferation of hematopoietic cells in
culture (Wilson & Trumpp, 2006). Studies in the 1970s indicated that undifferentiated hema‐
topoietic cells are localized close to the endosteal bone surface, and that differentiated cells
move toward the central axis of the marrow. The endosteum is the interface between bone and
bone marrow and constitutes a reservoir of HSCs that can be mobilized, restoring hematopoi‐
esis in response to tissue injury. Although bone is a hard and stiff organ, the endosteal niche
is not so; it rather presents plasticity and is under self and systemic regulation.
After the identification of niches in the endosteal region, cells in the endothelial lining were
proposed as a cellular component of the niche. However, heterogeneous cell populations were
found in endosteal regions that included mature bone lining cells, osteoblasts, and preosteo‐
blasts (Oh et al., 2010).
2.1. Osteoblastic cells
Osteoblasts are responsible for the production of matrix, which they secrete at the site of
the bone, as well as for bone mineralization. Eventually, osteoblasts either get surround‐
ed  by  matrix  and  end  up  as  osteocytes  or  they  become  bone-lining  cells,  which  is  a
reversible process (ter Ruurne et al., 2010). The bone-forming osteoblastic cells are crucial
players  for  the  homeostasis  of  the  hematopoietic  tissue with its  high turnover.  In  1994,
primary human osteoblasts were shown to stimulate the proliferation of primitive CD34+
hematopoietic  progenitors  in  vitro,  which  raised  the  possibility  that  osteoblasts  are
involved in hematopoiesis (Nagasawa et al., 2011).
Involvement  of  osteoblastic  cells  in  HSC  regulation  and  maintenance  in  vivo  was  first
reported by two groups using engineered mouse models (Lymperi et al.,  2010). The first
study,  a  bone  morphogenic  protein  (BMP)  receptor  IA  (BMPRIA)  conditional  knockout
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mouse was used to show that an increase in the number of osteoblastic cells was correlat‐
ed with an increase in the number of HSCs.
HSCs proliferation and differentiation is regulated by a wide variety of cytokines, growth
factors, and other signaling molecules. Osteoblastic cells synthesize a number of cell-signaling
molecules that appear to contribute to the maintenance and regulation of HSCs by the
endosteal niche such as (table1):
• Jagged, a ligand for Notch receptors expressed on HSCs which is markedly upregulated
with activation of the osteoblast by the parathyroid hormone. Activation of Notch receptors
on HSCs has been shown to inhibit differentiation and enhance their self renewal capacity
in vitro (Butler et al., 2011). Notch signalling is important in vivo for controlling HSC self
renewal and differentiation during hematopoietic stress conditions (Lilly et al., 2011).
• Thrombopoietin (THPO) and angiopoietin (Ang-1), which bind to cell surface receptors
MPL and Tie2, respectively, are expressed on HSCs. These cytokines are thought to be
important as THPO and Ang-1 knockout mice have decreased numbers or defects in bone
marrow HSCs. The interaction of Ang-1 with its Tie2 receptor activates β1-integrin and N-
cadherin, enhances quiescence, and maintains the long term repopulating ability of HSCs;
it also protects against apoptosis by activating the PI3K pathway (Lilly et al., 2011)
• Osteopontin, a matrix glycoprotein expressed by the osteoblasts supports the adhesion of
HSC to the osteoblastic niche and negatively regulates HSC proliferation, contributing to
the maintenance of a quiescent state (Guerrouahen et al., 2011).
• The chemokines  and their  receptors  can control  HSC behaviour  The best  understood
chemokine, in this regards,  is  the stromal-derived factor-1 (SDF-1),  also called chemo‐
kine  C-X-C  motif  ligand  12  (CXCL12).  The  SDF-1  receptor  is  the  C-X-C  chemokine
receptor type 4 (CXCR4) and is expressed on HSCs and progenitors (Lilly et al.,  2011).
SDF-1 belongs to α-chemokines that  functions as  chemoattractant  for  both committed
and primitive hematopoietic progenitors and regulates embryonic development includ‐
ing organ homeostasis (Ratajczak et al., 2006). SDF-1 counteracts with its cognate receptor
CXCR4,  that  is  widely  expressed  in  several  tissues  including  hematopoietic  and
endothelial cells. SDF-1/CXCR4 signaling plays a critical role during embryonic develop‐
ment  by  regulating  B-cell  lymphopoiesis,  myelopoiesis  in  bone  marrow  and  heart
ventricular  septum  formation.  In  addition,  SDF-1  has  been  shown  to  mediate  the
recruitment  of  endothelial  progenitor  cells  (EPCs)  from  the  bone  marrow  through  a
CXCR4 dependent mechanism suggesting the functional role in vasculogenesis in which
EPCs could form blood vessels (Chotinantakul & Leeanansaksiri, 2012).
• Both HSC and osteoblasts express N-cadherin, and bone marrow imaging studies suggest
that spindle-shaped bone-lining osteoblasts (so-called SNO cells) communicate with HSC
through N-cadherin interactions. BrdU incorporation studies demonstrated that quiescent
HSCs with moderate N-cadherin reside close to osteoblasts which have high N-cadherin
expression. Furthermore, upregulation of N-cadherin on osteoblasts increases adherence of
HSC on the endosteal surface, which is associated with HSC quiescence and diminished
differentiation (Coskun & Hirschi, 2010).
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• Early HSC characterization studies led to the discovery of a growth factor secreted by
osteoblasts, called stem cell factor (SCF) that regulates HSC activity in vivo and self-renewal
in vitro. HSCs express a transmembrane receptor tyrosine kinase called stem cell factor
receptor (C-Kit) that can bind to SCF, activating intracellular signaling important for HSC
regulation (Audet et al., 2002).
• Members of the Wingless (Wnt) family of lipid-modified proteins have been also investi‐
gated in hematopoiesis. The Frizzled (Fzd) receptors act as Wnt receptors which activate
downstream signaling in the Ctnnb1-dependent canonical and non-canonical pathways.
Several components of the Wnt signaling machinery have been shown to play a role in HSC
self-renewal. Wnt signaling is important in bone formation and in enlargement of endosteal
surfaces. Several lines of evidence suggest that Wnt signaling in endosteal stromal cells may
affect HSC maintenance, not by intrinsic signals, but by signals originated from the stromal
cells. Wnt signaling may not be intrinsically involved in the maintenance of normal HSC
during hemostasis or self-renewal. However, there are data suggesting that changes of Wnt
signaling in endosteal stromal cells affect HSC maintenance through extrinsical mechanisms
(Renstrom et al., 2010).
Molecule Function
Jagged (Notch receptor) Control HSC self-renewal and differentiation during
hematopoietic stress conditions
Thrombopoietin and angiopoietin Maintenance of HSC in the niche in quiescence state
with a link to cell-cycle control
Osteopontin Maintenance of a quiescent state
SDF-1 (or CXCL12) Expressed in the stromal cells; attracts HSC
CXCR-4 Expressed in HSCs; receptor of SDF-1
N-cadherin HSC quiescence and decrease in differentiation
SCF Activation of intracellular signaling important for HSC
regulation
Wnt HSC self-renewal
Table 1. Molecules that regulate HSC activity
2.2. Endothelial cells
Endothelial cells were proposed to be important in the HSC microenvironment. In vivo and
tissue section imaging studies localize HSCs next to endothelial cells. Also, endothelial cells
secrete soluble factors that can expand human primitive hematopoietic cells ex vivo. However,
endothelial cells have not yet been shown to be a necessary regulatory component of the HSC
microenvironment in vivo (Frisch et al., 2008).
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2.3. Osteoclasts
These cells are formed by fusion of multiple granulocyte–macrophage progenitor cells, a
process mediated by osteoblasts. It reabsorb the mineralized bone matrix formed by chondro‐
cytes or osteoblasts and located in endosteal niches. The role of osteoclasts in hematopoiesis
remains a controversial issue. It has been reported that osteoclasts degrade endosteal niche
components and enhance mobilization of hematopoietic progenitor cells (Kollet et al., 2006).
Enzymes secreted by osteoclasts are responsible for the release of HSCs from the endosteal
niche. These enzymes are able to cleave factors that promote the interaction between HSCs
and their niche. On the other hand, results have been published that suggest that osteoclast
activity can promote lodgment of HSCs at the endosteal niche (ter Huurner et al., 2010). Further
studies will be needed to clarify how osteoclasts regulate hematopoietic stem and progenitor
cell behavior (Sugiyama & Nagasawa et al., 2012).
3. Vascular niche
Hematopoiesis and vascularization occur concurrently during development. In fact, HSCs and
endothelial cells are derived from the same progenitor cells (termed hemangioblasts) at the
embryonic stage and are closely related to the ontogeny of hematopoiesis (Yin & Li, 2006). The
presence of a second specialized HSC microenvironment in the bone marrow has recently been
postulated, as a large proportion of CD150+ HSCs was observed to be attached to the fenes‐
trated endothelium of bone marrow sinusoids (Wilson & Trumpp, 2006).
The  vascular  niche  promotes  proliferation and differentiation,  active  cycling,  and short-
term HSCs. Most purified HSCs, containing CD150+ CD48− CD41− Lin− cells, were found
to be mainly associated with the sinusoidal endothelium lining blood vessels, suggesting
that endothelial cells create a cellular niche for HSCs. Endothelial cells in the vascular niche
environment contacting HSCs also provide maintenance signals on the HSC behavior (Can,
2008). However, it is essential to keep in mind that vasculature is not compartmentalized
to  the  central  region of  bone marrow and,  in  fact,  the  endosteal  region of  bone is  also
vascularized.  Therefore,  the proposed osteoblast  and vascular niches within marrow are
not completely separable, and may function interdependently to generate and sustain HSCs
(Coskun & Hirschi, 2010).
The vascular niche has been shown to produce factors important for mobilization, homing,
and engraftment of HSC. Endothelial cells expressing vascular cell-adhesion molecule-1
(VCAM-1) associate closely with megakaryocytes and their progenitors through VLA-4 in
response to chemotactic factors, stromal cell-derived factor-1 (SDF1) and fibroblast growth
factor-4 (FGF4); thus, they provide a niche for megakaryocyte maturation and platelet
production (Avecilla et al., 2004).
Two perivascular cell groups that possess mesenchymal cell properties function as niche cells:
1. CXC chemokine ligand 12 (CXCL-12)-abundant reticular cells (CAR cells), and 2. Nestin
234+ mesenchymal stem cells (Nakamura-Ishizu & Suda, 2012).
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3.1. CAR cells
In  human  bone  marrow,  such  reticular  cells  constitute  the  subendothelial  (adventitial)
layer of  sinusoidal  walls  projecting a reticular  process that  is  in close contact  with HSCs.
Interestingly,  these  reticular  cells  were  derived  from  a  specific  subset  of  mesenchymal
cells  (CD146þ)  that  had  been  shown  to  produce  either  reticular  or  endosteum  of  the
ectopic  hematopoietic  microenvironment  (HME),  referred  to  as  skeletal  stem  cells
(Sugiyama & Nagasawa,  2012).
These cells  have recently been shown to be high secretors  of  SDF-1 (CXCL12),  and as a
result  they  have  been  named  CXCL12  abundant  reticular  (CAR)  cells.  Phenotypically
they express  VCAM-1,  CD44,  238 platelet-derived growth factor  receptor  (PDGFRα and
PDGFRβ)  and  possess  adipogenic  and  osteogenic  differentiation  capacity  (Nakamura-
Ishizu  &  Suda,  2012).  Histochemical  analysis  revealed  that  all  bone  marrow  sinusoidal
endothelial  cells  are  surrounded by  a  proportion  of  CAR cells,  however,  CAR cells  do
not  express  the  pan-endothelial  marker  platelet/endothelial  cell-adhesion  molecule  1
(PECAM-1)/CD31 or  the smooth muscle  cell  maker and smooth muscle  α-actin (SMαA),
suggesting  that  they  are  different  from  endothelial  cells  and  smooth  muscle  cells
(Sugiyama & Nagasawa,  2012).
The  depletion  of  CAR cells  using  a  diphtheria  toxin  mouse  model  reduces  the  cycling
of  lymphoid  and  erythroid  progenitors,  as  well  as  the  total  HSC  cell  number  and  cell
cycling,  reflecting  that  CAR  cells  regulate  the  proliferation  of  HSC  rather  than  its
quiescence.  Ablation of  CAR cells  did not  influence other niche cell  compartments  such
as endothelial  cells  or  osteoblasts  (Lilly  et  al.,  2011).  However,  results  based on the short
term duration of  the CAR cell  deletion underestimate the influence that  CAR cells  may
convey on other  niches.
3.2. NES+ cells
Nestin is an intermediate filament protein that was originally identified as a marker of neural
progenitor. Its expression has subsequently been detected in a wide range of progenitor cells
and endothelial cells (Sugiyama & Nagasawa, 2012). NES+ MSCs can be differentiated into
adipocytes, osteoblasts and chondrocytes, and their HSC regulatory function is modified by
sympathectomy or by treatment with G‑CSF (which downregulates HSC ability to express
CXCL12, SCF, angiopoietin, IL7, and vascular cell adhesion molecule 1 (VCAM1)) (Wang &
Wagers, 2011). Nestin+ cells exhibited multilineage differentiation into various mesenchymal
cell lineages including osteoblasts (Nagasawa et al., 2011).
Nestin+ cells express high levels of genes involved in the regulation of HSCs: Cxcl12, c-kit
ligand, angiopoietin-1, interleukin-7, vascular cell adhesion molecule-1 and osteopontin.
Recently, it was demonstrated that bone marrow CD169+ macrophages are able to maintain
the HSCs through CXCL12 levels and through nestin 265+ niche cells, which emphasizes the
dense crosstalk among various niches (Nakamura-Ishizu & Suda, 2012).
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4. The relationship between the endosteal and vascular niches
It is well known that HSC circulation involves HSCs leaving the bone marrow, entering
in  the  vascular  system  (mobilization),  and  returning  to  the  bone  marrow  (homing).
However, the underlying physiological function of these events is not well understood (Yin
& Li, 2006).
The endosteal niche, localized at the inner surface of the bone cavity and with abundant
osteoblasts, might serve as a reservoir for long-term HSC storage in a quiescent state, whereas
the vascular niche, which consists of sinusoidal endothelial cell lining blood vessel, provides
an environment for short-term HSC proliferation and differentiation. Both niches act together
to maintain hematopoietic homeostasis or to restore it after damage (Guerrouahen et al., 2011).
Based  on  in  vivo  immunofluorescence  with  signaling  lymphocytic  activation  molecule
(SLAM), a family of cell surface receptors, Kiel & Morrison (2006) identified the vascular
niche of HSCs in several tissues, also known as the sinusoidal endothelial niche. Though
the two kinds of  HSCs niches were anatomically and functionally defined,  accumulated
data  suggests  that  endosteal  and vascular  niches  overlap  in  both  location  and function
(Figure  1).  Three  dimension  imaging  determined  that  there  are  abundant  vascular
structures on the surfaces of trabecular bones, and that those vessels and endosteal surfaces
are intimately coupled with each other within a trabecular region (Wang & Wargers, 2011).
The major difference between both microenvironments is the oxygen level. Higher in the
vascular  niche  than  in  the  endosteal  niche  under  hypoxia,  HSCs  would  move  to  the
vascular  niche  and  resume then  the  cell  cycle  in  order  to  restore  hematopoiesis.  HSCs
would then return to the endosteal niche where they would again be maintained in the
G0 state (Parmar et al., 2007).
Numerous examples of HSC-endothelial cross-talk exist, although most studies have focused
on the function of the endothelial cell in HSC homing. Recent investigations have suggested
roles for the vascular CAMs E- and P-selectin and VCAM-1 in HSC homing to bone marrow,
as well as for the chemokine SDF-1 (Calmone & Sipkins, 2008).
5. HSCs outside their niches
To turn the situation even more complex, HSCs are not static. Although the vast majority of
HSCs in adult humans is located in the bone marrow, HSCs show remarkable mobility. In
response to specific signals they can exit and re-enter the endosteal bone-marrow HSC niche,
processes known as mobilization and homing, respectively (Wilson et al., 2006).
The use of mobilizing regimens for the collection of HSCs from the peripheral  blood of
donors  rather  than  from the  BM soon  became common clinical  practice  in  transplanta‐
tion settings far before understanding the mechanisms underlying this phenomenon. The
most  efficient  cytokine  currently  used  in  the  clinical  practice  to  mobilize  HSCs  is  the
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granulocyte colony-stimulating factor (G-CSF) or its pegylated form (Peg G-CSF) used in
a single administration. It was then shown that G-CSF-induced mobilization involved the
modulation of the SDF-1/CXCR4 axis, whereby the reduction of the SDF-1 levels and the
upregulation of its receptor CXCR4 were correlated with stem cell mobilization. Howev‐
er, although evidence suggested that the mobilization effect of G-CSF lies in its capacity
to modify the SDF1 gradient (CXCL12) between the bone marrow and the peripheral blood,
favoring  the  release  of  HSCs,  the  exact  mechanism  by  which  this  occurs  has  not  been
completely clarified (Lymperi et al., 2010).
The release of  HSCs not only occurs during mobilization but it  is  also observed during
homeostasis,  when a small  number of  HSCs are constantly released into the circulation.
Although their  precise physiological  role remains unclear,  they might provide a rapidly
accessible source of HSCs to repopulate areas of injured bone marrow (Wilson et al., 2006).
6. HSC niches and disease
The elucidation of the cellular components and molecular effectors of the HSC niche has
raised  obvious  interest  on  whether  analogous  regulatory  processes  are  involved  in  the
biology  of  bone  marrow  tumors.  Increasing  evidences  point  toward  critical  roles  of
nonautonomous,  microenvironmental  factors  in  the development,  progression,  and drug
resistance  of  different  malignancies  evolving  in  the  bone  marrow (Carlesso  & Cardoso,
2010). Although most hematopoietic malignancies are likely to arise from mutations that
inappropriately activate hematopoietic cell proliferation and survival pathways, recent data
demonstrate that hematopoiesis can also be dysregulated by alterations in the niche, with
defects  in  HSCs  themselves  arising  secondarily  (Wang  et  al.,  2012).  The  extent  of  the
reliance of these tumors on the microenvironment appears to be dependent upon the type
and  stage  of  malignancy.  At  one  extreme  is  a  neoplastic  growth  that  is  dependent  on
dysregulated cell-cell interactions and signalling pathways within the microenvironment.
At the other end of the spectrum there are malignancies that exhibit an absolute depend‐
ence on normal microenvironmental cues for disease progression, such as the expression
of specific cytokines and growth factors (Guerrouahen et al., 2011).
Several studies have provided insights into the role of altered microenvironment signaling
leading to myelofibrosis, myeloma, and myelodysplastic syndromes (Noll et al., 2012).
Lataillade et al. (2008) suggested that an imbalance between endosteal and vascular niches may
be important in idiopathic disorder characterized by bone marrow fibrosis (primary myelo‐
fibrosis), leading to the development of clonal stem cell proliferation. The most compelling
recent example comes from work in which miRNA processing was disrupted in osteoblast
precursors and mice developed myelodysplasia, which in rare cases progressed to myeloid
leukaemia by 3 weeks of age; notably, HSCs transplanted from these mice into wild-type
recipients did not transfer myelodysplasia, indicating that the HSCs were not intrinsically
competent to produce pathologic changes (Hosokawa et al., 2010).
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6.1. Leukemic Stem Cells
Leukemic stem cells (LSCs) were first described in 1994. The paradigm of cancer stem cells
considers leukemia a hierarchical disease process whose growth is sustained by a rare
population of LSCs. LSCs maintain the capacity to self-renewal and give rise to malignant
progeny with extensive proliferative potential (Flynn & Kaufman, 2007).
It  has  been  speculated  that  the  transformation  involves  at  least  a  2-step  process,  one
mutation blocking differentiation and another event conferring a proliferative advantage
to its progeny (figure 2).  Other LSCs may result from dedifferentiation of more commit‐
ted progenitors that reacquire the ability of self-renewal prior to accumulating transform‐
ing mutations (Blair et al., 1998).
Figure 1. Reticular niches created by mesenchymal progenitors might maintain and regulate HSCs. A model for
the localization of HSCs and their association with candidate cell niches in the bone marrow (Modified from Nagasa‐
wa et al., 2011).
There is much greater heterogeneity in the phenotype of LSCs than has been previously
thought, indicating the inadequacy of the currently used surface antigens or biochemical
markers as criteria for LSCs isolation. Evidences from the literature suggest that LSCs are a
moving target and its identification depends on many factors including the receptiveness of
the murine model used in the experimental design. In addition, it is debatable whether results
derived from highly artificial animal models could be extrapolated for the situation in human
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(Lutz et al., 2012). So far there are only few data analyzing the diversity of LSC in individual
patients with acute myeloid leukemia (AML). It has been shown that CD34+CD38− subpopu‐
lations are heterogeneous in the distribution of mutations compared to the whole blast
population at diagnosis. The situation might be similar to the genetic heterogeneity detected
in childhood acute lymphoblastic leukemia (Anderson et al., 2011).
In BCR-ABL–associated leukemias, the transformation occurs at the stem cell and progen‐
itor  cell  level  depending  on  the  phenotype  and fusion  transcript  isoform (Castor  et  al.,
2005). It is a population of highly quiescent HSCs expressing BCR-ABL1 that can be isolated
from untreated chronic myeloid leukemia (CML) patients and from imatinib-treated CML
patients.  These  quiescent,  non-proliferating  CD34+  CML  cells  have  been  shown  to  be
resistant to a range of pro-apoptotic stimuli including chemotherapy and tyrosine kinase
inhibition  with  imatinib.  The  quiescent  BCR-ABL1-expressing  HSCs can  be  regarded as
LSCs.  By  way  of  comparison,  proliferating  CD34+  progenitors  in  CML  are  sensitive  to
imatinib-induced apoptosis that is significantly mediated by the pro-apoptotic BCL-2 family
proteins Bim and Bad (Kuroda et al., 2006; Ng, 2012).
Figure 2. Putative mechanisms for AML stem cell and niche interactions in vivo. The niche provides support for
self-renewal, quiescence, homing, engraftment, and proliferative potential for HSCs. LSCs may impair the function of
the normal HSC niche by direct invasion or secretion of substances such as stem cell factor. LSCs can infiltrate these
niches leading to enhanced self-renewal and proliferation, enforced quiescence, and resistance to chemotherapeutic
agents. (Modified from Lane et al., 2009).
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In analogy to normal HSC, LSC also need the marrow niche for their malignant self-renewal
and dormant state. Perturbing the binding of LSC to the marrow niche through disruption of
the adhesive forces might therefore “mobilize” LSC from their protective environment.
Molecules such as CD44, CXCR4, N-cadherin, among others, appear to play significant
regulatory roles for HSC and LSC trafficking, signaling and homing to their marrow niche
(Sugiyama et al., 2006; Spoo et al., 2007; Teicher & Fricker, 2010; Lutz et al., 2012). LSC may also
hijack these pathways in a number of ways, for example, up-regulation of the α4β1 integrin,
VLA-4, which mediates adhesion to fibronectin and VCAM-1. Patients with undetectable
VLA-4 levels on leukemic blasts had an excellent response to chemotherapy, perhaps indicat‐
ing that this pathway may mediate a stromal influence on sensitivity to chemotherapy
(Matsunaga et al., 2003). These data suggest that interactions between VLA-4 on leukemic cells
and fibronectin expressed on BM stromal cells may modulate chemotherapy sensitivity (Doan
& Chute, 2012). Another example is the CD44, the receptor for hyaluronic acid, which is also
important for hematopoietic stem and progenitor cell homing to the vascular niche. In both, a
mouse model of chronic myelogenous leukemia and a xenograft model of human AML,
treatment with an anti-CD44 antibody resulted in LSC mobilization from the niche, LSC
differentiation and LSC eradication (Krause et al., 2006).
6.2. Multiple myeloma
A number of pathways and cell types have been shown to affect the behaviour of both HSCs
in normal hematopoiesis and the malignant myeloma plasma cells. It is through these
regulated interactions with cell populations and signalling pathways within the bone marrow
microenvironment that myeloma cells are believed to ‘hijack' the normal hematopoietic niche
to aid the extensive growth and proliferation of tumour cells (Noll et al., 2012). Multiple
myeloma (MM) is characterized by the proliferation of a malignant plasma cell clone, initially
located in the bone marrow microenvironment. This illness is unique among hematological
malignancies in its capacity to cause great bone destruction, leading to pathologic bone
fractures and intractable bone pain. This result is the consequence of an imbalance between
osteoblastic and osteoclastic activity induced by MM cells (Corre et al., 2007).
Normal  plasma cells  are  dependent  on specific  signals  from bone marrow stem cells  to
regulate their differentiation, growth and localization. These same signals are required for
myeloma cell growth and survival, supporting the notion that the bone marrow provides
a permissive environment for disease development (Degrassi et al., 1993). It is evident that
the presence of myeloma cells in the bone marrow modulates the expression of cytokines
from stromal cells, which enhances their ability to modify the microenvironment to support
malignant growth (Noll et al., 2012).
7. Conclusion
During the past few years, the theoretical concept of a specific stem cell microenvironment
that was proposed in the 1960s and 1970s, has finally received greater attention. As mentioned,
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pinpointing the exact location of the hematopoietic stem cell in vivo within the bone marrow
is difficult, despite advancements in immunohistochemistry, genetic marking of cells, and in
vivo imaging. Early studies showed that hematopoietic progenitor and stem cells were highly
present near the endosteal bone surface, whereas more mature cells were selectively localized
centrally within the bone marrow cavity.
The development of hematologic malignancies may be a multi-step process involving muta‐
tions both in the hematopoietic cells and/or in cells present in the supportive microenviron‐
ment. Targeting the niche-HSCs, niche-leukemic cells, or niche itself in hematopoietic
malignancies is an attractive potential addition to the therapeutic possibilities. The challenge
of stem cell biology is to translate the expansion of biological insights into clinically meaningful
improvements for patients with hematological malignancies and related disorders.
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